ProCE Banner Activity

Understanding the Role of LAG-3 in Malignancies: A Summary Resource

PDF
Download this PDF summary resource to learn more about LAG-3 as the latest validated immune checkpoint therapeutic target, the first approved LAG-3 therapy relatlimab, and investigational agents targeting LAG-3 across multiple tumor types.

Released: March 23, 2022

Expiration: March 22, 2023

No longer available for credit.

Share

Faculty

Krista M. Rubin

Krista M. Rubin, MS, RN, FNP-BC

Nurse Practitioner
Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Krista M. Rubin, MS, RN, FNP-BC

Nurse Practitioner
Center for Melanoma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts